Open AccessThe Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
Author(s) -
Tang LingLong,
Chen YuPei,
Chen ChuanBen,
Chen MingYuan,
Chen NianYong,
Chen XiaoZhong,
Du XiaoJing,
Fang WenFeng,
Feng Mei,
Gao Jin,
Han Fei,
He Xia,
Hu ChaoSu,
Hu Desheng,
Hu GuangYuan,
Jiang Hao,
Jiang Wei,
Jin Feng,
Lang JinYi,
Li JinGao,
Lin ShaoJun,
Liu Xu,
Liu QiuFang,
Ma Lin,
Mai HaiQiang,
Qin JiYong,
Shen LiangFang,
Sun Ying,
Wang PeiGuo,
Wang RenSheng,
Wang RuoZheng,
Wang XiaoShen,
Wang Ying,
Wu Hui,
Xia YunFei,
Xiao ShaoWen,
Yang KunYu,
Yi JunLin,
Zhu XiaoDong,
Ma Jun
Publication year - 2021
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1002/cac2.12218
Subject(s) - nasopharyngeal carcinoma , medicine , clinical oncology , oncology , incidence (geometry) , medical physics , intensive care medicine , radiation therapy , cancer , physics , optics
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi‐disciplinary team comprising of experts from all sub‐specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence‐based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow‐up of NPC, which aim to improve the management of NPC.